Literature DB >> 21048816

Concerning Chapter 5 - Human Albumin; in Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives, 4th ed. Transfus Med Hemother 2009;36(6):399-407.

Albert Farrugia1.   

Abstract

Entities:  

Year:  2010        PMID： 21048816      PMCID： PMC2914418          DOI： 10.1159/000293349

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN： 1660-3796            Impact factor:   3.747


× No keyword cloud information.
  18 in total

1.  Pentastarch versus albumin in cardiopulmonary bypass prime: impact on blood loss.

Authors:  E J Keyser; D A Latter; J E Morin; A A Murshid; F Denis; B de Varennes
Journal:  J Card Surg       Date:  1999 Jul-Aug       Impact factor: 1.620

Review 2.  Complexity and contradiction in clinical trial research.

Authors:  R I Horwitz
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

Review 3.  Human albumin solution for resuscitation and volume expansion in critically ill patients.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

4.  Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials: ATTENTION: The analysis and conclusions of this article are being revised by the authors. This is due to the journal Anesthesia and Analgesia's retraction of a paper by Dr. Joachim Boldt, an author in seven of the studies analyzed in this review. As such, the editors of Open Medicine recommend interpreting this review with extreme caution until Zarychanski et al. publish a new analysis and interpretation in Open Medicine. For more information, see Anesthesia and Analgesia's press release.

Authors:  Ryan Zarychanski; Alexis F Turgeon; Dean A Fergusson; Deborah J Cook; Paul Hébert; Sean M Bagshaw; Danny Monsour; Lauralyn McIntyre
Journal:  Open Med       Date:  2009-10-27

5.  Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: a prospective randomized trial.

Authors:  Alexey A Schramko; Raili T Suojaranta-Ylinen; Anne H Kuitunen; Sinikka I Kukkonen; Tomi T Niemi
Journal:  Anesth Analg       Date:  2009-01       Impact factor: 5.108

Review 6.  Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function.

Authors:  Allison B Dart; Thomas C Mutter; Chelsea A Ruth; Shayne P Taback
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

7.  The risk associated with hyperoncotic colloids in patients with shock.

Authors:  Frédérique Schortgen; Emmanuelle Girou; Nicolas Deye; Laurent Brochard
Journal:  Intensive Care Med       Date:  2008-08-07       Impact factor: 17.440

8.  Molecular adsorbent recirculating system (MARS) application in liver failure: clinical and hemodepurative results in 22 patients.

Authors:  S Stefoni; L Colì; L Bolondi; G Donati; G Ruggeri; G Feliciangeli; F Piscaglia; E Silvagni; M Sirri; G Donati; O Baraldi; M L Soverini; G Cianciolo; P Boni; D Patrono; E Ramazzotti; R Motta; A Roda; P Simoni; M Magliulo; L C Borgnino; D Ricci; D Mezzopane; M L Cappuccilli
Journal:  Int J Artif Organs       Date:  2006-02       Impact factor: 1.595

9.  Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis.

Authors:  Tai-An Chen; Yu-Chen Tsao; Angela Chen; Gin-Ho Lo; Chiun-Ku Lin; Hsien-Chung Yu; Lung-Chih Cheng; Ping-I Hsu; Wei-Lun Tsai
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

10.  Crystalloid or colloid for resuscitation. Are we any the wiser?

Authors: 
Journal:  Crit Care       Date:  1999       Impact factor: 9.097
View more
  2 in total

1.  Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation.

Authors:  Martin David Berger; Bernhard Gerber; Kornelius Arn; Oliver Senn; Urs Schanz; Georg Stussi
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  As for the Past, as for 2010.

Authors:  Peter Schlenke; Walter Sibrowski
Journal:  Transfus Med Hemother       Date:  2010-02       Impact factor: 3.747
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.